1. Medtech Insight
  2. >>Business

Start-Up Spotlight: Elypta Targets World’s First Metabolism-Based Early Cancer Diagnosis

Chalmers University of Technology spin out takes a different route to cancer biomarker identification

 
• By Ashley Yeo

The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.

Start-up Spotlight

Diagnostic tools have rarely had such concerted attention as during COVID-19. And science advances have been moving modern diagnostic techniques, such as circulating tumor DNA biomarkers, epigenetic markers, DNA methylation and RNA screening, up the agenda.

But those technologies are not particularly sensitive to the early stages of cancer, said Elypta CEO Karl Bergman. The company...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

After Thought-Control Demo, Synchron Plans Pilot Study With Upgraded BCI On Path To Pivotal Trial

 
• By Marion Webb

Synchron is preparing a pilot study of its fully wireless, second-gen brain-computer interface after an ALS patient controlled an iPad solely by thought. If all goes as planned, Synchron’s BCI will move into pivotal trials in 2026.

Apreo Health Raises $130M, First Patient Treated In US Clinical Trial

 
• By Natasha Barrow

Apreo Health CEO Karun Naga talks to Medtech Insight about the company’s intentions for its Series B funding. The Breathe-3 clinical trial and early commercialization activities, involving physician education, are top priorities.

Execs On The Move: August 4–8, 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.